Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY.
According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology and Radiology segments growing by 24% YoY and 13% YoY respectively.
Also ReadBudget 2025 Expectations: Diagnostics sector leaders urge govt to strengthen public-private partnerships, offer tax incentives
Meanwhile, revenue from franchise surged by 24% YoY, and partnership revenue saw 23% YoY growth. The consolidated gross margin stood at 73%, and normalized EBITDA margin was 30%.
Also Read Q3 Results: HDFC Bank, HUL, BPCL posts profit rise of 2.22%, 19.18%, 19.63%, respectively Q3 Results: UltraTech profit up 16.98%, Adani Green profit surges 85.16%; others releasing Q3 results today ‘What’s the use of money if planet is destroyed’: Nithin Kamath reveals Zerodha’s Rainmatter invested Rs 275 cr across climate, health startups in 2024 Immuneel Therapeutics launches CAR T-cell therapy for blood cancer in India
The company’s consolidated reported EBITDA grew by 32% YoY, while PAT increased by 30% YoY.
» Read More
